4AA Preclinical
Testagen
Synthetic gonadal tetrapeptide (Lys-Glu-Asp-Gly) from the Khavinson school studied for HPG-axis normalisation, testosterone biosynthesis support, and spermatogenic function in preclinical and limited clinical models.
In Plain English:
Testagen is a four-amino-acid chain — lysine, glutamic acid, aspartic acid, and glycine (KEDG) — synthesised as the putative active tetrapeptide of a testicular tissue extract developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. The compound is also sometimes catalogued as Anterior Pituitary Peptide (APP) because early avian studies examined KEDG alongside pituitary-derived peptides; the primary organ-specificity designation in modern vendor literature is gonadal/testicular. In the Khavinson peptide-bioregulation model, the tetrapeptide is expected to enter cell nuclei and bind DNA and histone proteins in target tissue, thereby upregulating steroidogenic enzyme gene expression in Leydig cells and supporting spermatogenesis. One small non-randomised clinical study in Ukrainian urological patients documented improvements in uroflowmetric parameters and serum total testosterone in men with chronic prostatitis and androgenic deficiency. Animal studies demonstrated thyroid-hormone and thymus morphology restoration in hypophysectomised birds treated with KEDG. In-vitro biochemistry work confirmed KEDG binds N-terminal domains of wheat histones H1, H2B, H3, and H4. The overall human evidence base is the weakest in the Khavinson bioregulator family: one study, no randomisation, no independent replication, no pharmacokinetics, and no toxicology programme.
Research Maturity
Preclinical (~4–5 peer-reviewed papers (2011–2023); 1 non-randomised clinical study (N=36), rest preclinical; no RCTs or replication+ Studies)
Focus
Fertility Support
Male Hormonal Axis
Testicular Function
Origin
Identified and synthesised by Vladimir Kh. Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as part of the organ-specific 'cytogen' directed-synthesis programme. The parent complex is a testicular polypeptide extract from bovine tissue; KEDG was selected as the minimal bioactive sequence after amino-acid compositional analysis of testicular regulatory peptides. The compound is also marketed as the synthetic 'cytogen' Testagen® in Russian supplement markets (TD Peptid Bio / Khavinson institute formulation, 60 capsules × 0.2 mg KEDG each). Western research-peptide vendors began supplying lyophilised 20 mg vials from approximately 2019 onward.
Mechanism
Proposed primary mechanism is epigenetic gene regulation via direct DNA and histone interaction. Fedoreyeva et al. (2013, PMID 23581987) confirmed that KEDG binds FITC-labelled wheat histones H1, H2B, H3, and H4 at N-terminal peptide-binding motifs through fluorescence quenching; binding was sequence-specific and depended on both peptide and oligonucleotide primary structure. In gonadal tissue this is theorised to upregulate transcription of steroidogenic enzymes — StAR, CYP11A1, CYP17A1, 3β-HSD, and 17β-HSD — in Leydig cells, promoting testosterone biosynthesis. Supplementary mechanisms include: (1) HPG-axis normalisation — peptide proposed to restore hypothalamic-pituitary-gonadal signalling rather than act as a direct androgen secretagogue; (2) thyroid-axis activity — Kuznik et al. (2011, PMID 22268052) showed KEDG reduced hypophysectomy-induced pathological changes in thyroid morphology and normalised TSH, T3, and T4 concentrations in young chickens and old hens; (3) thymic morphology restoration — Pateyk et al. (2013, PMID 23658898) showed KEDG reversed thymic atrophy after neonatal hypophysectomy in birds, with more pronounced effects than the posterior-pituitary analog AEDG; (4) immune-cell differentiation — Khavinson et al. (2020, PMID 31808038) list KEDG among peptides that stimulate differentiation of monocyte/macrophage lineage cells; (5) cellular transport — computational modelling by Khavinson group (Biomolecules 2023) ranked KEDG among the highest-affinity ligands for LAT1, LAT2, and PEPT1 transporters, predicting efficient active cellular uptake. No crystal structures, genome-wide ChIP data, or receptor-binding constants specific to KEDG have been published.
Outcome
Serum total testosterone (Rossikhin et al. 2011 — elevated after one-month Testagen adjunct in n=36 men with chronic prostatitis/androgenic deficiency); uroflowmetric parameters (Rossikhin et al. 2011 — marked improvement); prostatic inflammation markers (Rossikhin et al. 2011 — decreased); thyroid morphology score in hypophysectomised birds (Kuznik et al. 2011, PMID 22268052 — pathological changes reduced, TSH/T3/T4 normalised); thymus cortex/medulla morphology in hypophysectomised chicks (Pateyk et al. 2013, PMID 23658898 — structural restoration, KEDG superior to AEDG); immune-cell differentiation markers (Khavinson 2020, PMID 31808038 — KEDG listed as stimulator); histone binding affinity (Fedoreyeva 2013, PMID 23581987 — confirmed fluorescence-quenching interaction with H1, H2B, H3, H4).
